A recent MedPage Today oncology roundup captures a wide span of cancer news. Regulators accepted a biologics license application for FYB206, a biosimilar to the blockbuster immunotherapy pembrolizumab (Keytruda), from Zydus Lifesciences and Formycon AG. The same update noted that the FDA expanded the bladder cancer indications for the interleukin-15 receptor agonist nogapendekin alfa inbakicept (Anktiva) to include bacillus Calmette-Guérin-unresponsive non-muscle invasive disease.
Trial results in the roundup were mixed. Bristol Myers Squibb announced that the investigational radiopharmaceutical 225Ac-Dotatate significantly improved progression-free survival versus standard care in a phase III trial for previously treated gastroenteropancreatic neuroendocrine tumors. In contrast, BioNTech reported that adding its mRNA cancer vaccine BNT113 to pembrolizumab did not improve progression-free survival in metastatic HPV-positive head and neck cancer.
The roundup also included several notable items beyond clinical data: the death of GI cancer researcher Rachna Shroff at age 47, new American College of Radiology guidance on breast masses in children, and an ecological analysis linking coastal microplastics to higher cancer rates. Because this is a single-source roundup, there are no differing source perspectives to weigh.